skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Global Search Configuration

Levers impacting access to prostate cancer treatment are very different in the US to the EU and the UK.

Download your complimentary prostate cancer infographic and discover:

Payer archetypes and trends in access

  • Least restrictive:US
  • Relatively unrestricted: France and Germany
  • Restrictive: Italian and Spanish regions
  • Most restrictive: UK

National Institute for Health and Care Excellence (NICE) applies arguably the most stringent cost-effectiveness analyses of any European nation

Levers impacting access to prostate cancer drugs in the US:

  • Insurers’ prior authorization criteria
  • Formulary tiering and patient co-pays
  • Oncology pathways

Levers impacting access to prostate cancer drugs in the five major EU markets:

  • National reimbursement decisions
  • Regional or local access criteria
  • Off-label prescribing controls
  • Budget limits
  • Risk-sharing agreements

Why Zytiga favored over Xtandi on Anthem’s oncology pathway

What Medicare’s shift to value-based payment means

The rebates and risk-sharing agreements that will be valuable in non-metastatic CRPC

Download the Infographic

Download now